Komori
Share Issuance and Disposal4576D.Western Therapeutics Institute, Inc.Pharmaceuticals

Monthly Update on the Exercise Status of the 13th Stock Acquisition Rights with Exercise Price Adjustment Provisions

The company reported the exercise status of the 13th Stock Acquisition Rights for June 2026. There were no exercises during the month, and no new shares were issued.

Worth reading
45Recurring
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
0
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause

発行済株式総数

0.00% (exercise ratio subject to exercise restrictions)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
¥80 (for each period during the reporting month) / Details of the adjustment clause: Not disclosed
Number of Stock Acquisition Rights
Total number issued: not disclosed; unexercised balance as of the end of the month preceding the target month: 9,098; unexercised balance as of the end of the target month: 9,098
Procedures under the Corporate Code of Conduct
Describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
31 July 2025: Issuance of the 13th Stock Acquisition Rights (with Exercise Price Adjustment Clause) (detailed amount: Not disclosed)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly report on the exercise status of stock acquisition rights with an exercise price adjustment clause
Dilution Rate0.00% (exercise ratio subject to exercise restrictions)
Total number of issued shares57,483,412 shares (as of the end of the month preceding the reporting month) → Not disclosed
Exercise price¥80 (for each period during the reporting month) / Details of the adjustment clause: Not disclosed
Number of Stock Acquisition RightsTotal number issued: not disclosed; unexercised balance as of the end of the month preceding the target month: 9,098; unexercised balance as of the end of the target month: 9,098
Procedures under the Corporate Code of ConductDescribes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing31 July 2025: Issuance of the 13th Stock Acquisition Rights (with Exercise Price Adjustment Clause) (detailed amount: Not disclosed)
Items this document does not state (21)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company reported the exercise status. No reason was given for the absence of exercises.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Monthly Update on the Exercise Status of the 13th Stock Acquisition Rights with Exercise Price Adjustment Provisions | D.Western Therapeutics Institute, Inc. (4576) timely disclosure | Komori